title: Spleen tyrosine kinase inhibitors reduce CD40L-induced proliferation of chronic lymphocytic leukemia cells but not normal B cells.
authors.affiliation: Centre for Immune Regulation, Institute of Clinical Medicine, University of Oslo, Norway.
authors.forename: Anna
authors.initials: A
authors.lastname: Parente-Ribes
authors.affiliation: Centre for Molecular Medicine Norway, Nordic EMBL Partnership, University of Oslo and Oslo University Hospital, Norway Biotechnology Centre, K. G. Jebsen Centre for Inflammation Research and K. G. Jebsen Centre for Cancer Immunotherapy, University of Oslo, Norway.
authors.forename: Sigrid S
authors.initials: SS
authors.lastname: Skånland
authors.affiliation: Centre for Immune Regulation, Institute of Clinical Medicine, University of Oslo, Norway Department for Haematology, Oslo University Hospital, Rikshospitalet, Oslo & Institute of Clinical Medicine, University of Oslo, Norway.
authors.forename: Simone
authors.initials: S
authors.lastname: Bürgler
authors.affiliation: Centre for Immune Regulation, Institute of Clinical Medicine, University of Oslo, Norway.
authors.forename: Audun
authors.initials: A
authors.lastname: Os
authors.affiliation: Centre for Immune Regulation, Institute of Clinical Medicine, University of Oslo, Norway.
authors.forename: Dong
authors.initials: D
authors.lastname: Wang
authors.affiliation: Centre for Immune Regulation, Institute of Clinical Medicine, University of Oslo, Norway KG Jebsen Centre for Influenza Vaccine Research, Institute of Clinical Medicine, University of Oslo, Norway.
authors.forename: Bjarne
authors.initials: B
authors.lastname: Bogen
authors.affiliation: Department for Haematology, Oslo University Hospital, Rikshospitalet, Oslo & Institute of Clinical Medicine, University of Oslo, Norway.
authors.forename: Geir E
authors.initials: GE
authors.lastname: Tjønnfjord
authors.affiliation: Centre for Molecular Medicine Norway, Nordic EMBL Partnership, University of Oslo and Oslo University Hospital, Norway Biotechnology Centre, K. G. Jebsen Centre for Inflammation Research and K. G. Jebsen Centre for Cancer Immunotherapy, University of Oslo, Norway Department of Infectious Diseases, Oslo University Hospital, Norway kjetil.tasken@ncmm.uio.no ludvig@medisin.uio.no.
authors.forename: Kjetil
authors.initials: K
authors.lastname: Taskén
authors.affiliation: Centre for Immune Regulation, Institute of Clinical Medicine, University of Oslo, Norway kjetil.tasken@ncmm.uio.no ludvig@medisin.uio.no.
authors.forename: Ludvig A
authors.initials: LA
authors.lastname: Munthe
mesh_terms: D018941:Antigens, CD19 / Q000235:genetics / Q000276:immunology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001402:B-Lymphocytes / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D023201:CD40 Ligand / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000276:immunology / Q000494:pharmacology; D049109:Cell Proliferation / Q000187:drug effects; D002986:Clinical Trials as Topic; D003514:Cyclohexylamines / Q000494:pharmacology; D015973:Gene Expression Regulation, Leukemic; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy / Q000235:genetics / Q000276:immunology / Q000473:pathology; D008213:Lymphocyte Activation; D009928:Organ Specificity; D010078:Oxazines / Q000494:pharmacology; D061251:Primary Cell Culture; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011725:Pyridines / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D015398:Signal Transduction; D013154:Spleen / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D000072377:Syk Kinase / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000276:immunology; D051996:Transcription Factor RelA / Q000235:genetics / Q000276:immunology; D048051:p38 Mitogen-Activated Protein Kinases / Q000235:genetics / Q000276:immunology
chemical_list: C571149:4-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-2-(2-aminocyclohexylamino)pyrimidine-5-carboxamide; D018941:Antigens, CD19; D000970:Antineoplastic Agents; C000604811:CD19 molecule, human; D003514:Cyclohexylamines; C510788:N4-(2,2-dimethyl-3-oxo-4H-pyrid(1,4)oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine; D010078:Oxazines; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D011743:Pyrimidines; D051996:Transcription Factor RelA; D023201:CD40 Ligand; C000606896:SYK protein, human; D000072377:Syk Kinase; D048051:p38 Mitogen-Activated Protein Kinases
keywords: CD40L (CD154); cancer microenvironment; chronic lymphocytic leukemia; small molecular pathway inhibitors